No distribution data
(Human) FDA prescribing information for the specific GLP-1 medication (for example Ozempic, Wegovy, Mounjaro, or Zepbound)
Other pharmacotherapies not based on entero-pancreatic hormones Several therapies that are not based on entero-pancreatic hormones are currently under evaluation for obesity and they represent further therapeutic options, considering their distinct mechanism of WL to the entero-pancreatic hormone therapies
Novo Nordisk plans to achieve more than 25 billion DKK ($3.72 billion) in obesity sales by 2025
40 In the LIVE trial, which evaluated the effects of liraglutide on LV function in stable chronic HF patients with and without diabetes, at the end of treatment patients from the liraglutide group were able to walk 28 65 m longer during the 6MWT, compared with 3 89 m for patients in the placebo group, with a mean difference of 24 m
We analyzed reviews from Trustpilot, ConsumerAffairs, and independent review platforms to identify consistent patterns in what users report